Topic: Hypertrophic Cardiomyopathy in the Genomic Era: Advances in Diagnosis and Therapeutics

Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiovascular disorders, characterized by left ventricular hypertrophy in the absence of other causative conditions. Recent advances in genomics have significantly transformed our understanding of the pathophysiology, diagnosis, and treatment of HCM. In the genomic era, novel insights into the genetic basis of the disease, combined with innovations in diagnostic technologies and personalized therapeutic approaches, offer new possibilities for improved patient management and outcomes.

This Special Issue seeks to explore the latest developments in the field of hypertrophic cardiomyopathy, with a particular focus on the integration of genomic data into clinical practice. We welcome original research, reviews, and clinical case studies that address topics including, but not limited to:
● The role of genetic mutations in the onset and progression of HCM;
● Novel therapeutic strategies, including gene-based therapies and pharmacologic innovations;
● Insights from large-scale genomic and phenotypic studies;
● Ethical considerations and challenges in genetic screening and counseling.

This Special Issue aims to provide a comprehensive overview of how genomic advancements are reshaping the landscape of hypertrophic cardiomyopathy, offering new perspectives on diagnosis and treatment. We encourage submissions from researchers, clinicians, and scholars working at the intersection of cardiology, genetics, and molecular medicine.

Hypertrophic cardiomyopathy, HCM, genomic, cardiovascular disorders

30 Jun 2025